Login to Your Account

Targanta Shares Plunge on cSSSI Complete Response

By Donna Young

Wednesday, December 10, 2008
Shares of Targanta Therapeutics Corp. plummeted 40 percent Tuesday after the Cambridge, Mass.-based firm said it received a complete response letter from the FDA asking for another study of oritavancin, an investigational antibiotic being developed for the treatment of complicated skin and skin structure infections (cSSSIs). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription